Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 1/20 | 0.37 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.37 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.37 |
| ▸ | TRPV4 | Q9HBA0 | 3/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | PKLR | P30613 | 1/20 | 0.33 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.30 |
| ▸ | CCR2 | P41597 | 1/20 | 0.30 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29835175 | 1.00 | SLC1A3 (0.37) | SLC1A3SLC1A2SLC1A1TRPV4CA12 | |
| SCHEMBL29669013 | 0.83 | TRPV4 (0.41) | TRPV4CA12CA1CA2CA7 | |
| SCHEMBL29669007 | 0.83 | TRPV4 (0.41) | TRPV4CA12CA1CA2CA7 | |
| SCHEMBL320432 | 0.83 | TRPV4 (0.41) | TRPV4CA12CA1CA2CA7 | |
| SCHEMBL1501202 | 0.83 | TRPV4 (0.41) | TRPV4CA1CA2PKMPTGES2 | |
| SCHEMBL30485974 | 0.83 | TRPV4 (0.41) | TRPV4CA1CA2PKMPTGES2 | |
| SCHEMBL1094769 | 0.81 | TRPV4 (0.32) | TRPV4CA12CA1CA2CA7 | |
| SCHEMBL384682 | 0.81 | PKM (0.38) | TRPV4CA12CA1CA2CA7 | |
| SCHEMBL1349380 | 0.81 | CA1 (0.35) | TRPV4CA12CA1CA2CA7 | |
| SCHEMBL29835220 | 0.81 | PKM (0.38) | TRPV4CA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3728194-B1 | QUINOLINE SULFONAMIDE COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS | OTAGO INNOVATION LTD (NZ) | 2025-06-04 | — | — | EP | disclosed |
| US-20250115687-A1 | PRODUCTION METHOD FOR SOLID CATALYST COMPONENT FOR POLYMERIZING OLEFINS, AND CATALYST FOR POLYMERIZAING OLEFINS | FORMOSA PLASTICS CORP USA (US) | 2025-04-10 | — | — | US | disclosed |
| CN-118344270-A | Fluorine-containing diphenyl sulfone acaricide and preparation method thereof | 柳州市惠农化工有限公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-117624140-A | CXCR4 antagonists, methods of making and uses thereof | 杭州师范大学 | 2024-03-01 | — | — | CN | disclosed |
| CN-117586190-A | Benzimidazole compound containing substituted benzenesulfonyl or salt thereof, preparation method, insecticidal acaricide, parasite control agent and application | 青岛康乔药业集团有限公司 | 2024-02-23 | — | — | CN | disclosed |
| CN-114957053-B | Oxoethylene compound or pharmaceutically acceptable salt thereof, preparation method and application thereof, pharmaceutical composition and application thereof | 中国医学科学院医药生物技术研究所 | 2023-12-22 | — | — | CN | disclosed |
| US-11691949-B2 | Quinoline sulfonamide compounds and their use as antibacterial agents | OTAGO INNOVATION LIMITED (NZ) | 2023-07-04 | — | — | US | disclosed |
| WO-2022258023-A1 | COMPOUND AS CDK KINASE INHIBITOR AND USE THEREOF | 郑州同源康医药有限公司 | 2022-12-15 | — | — | WO | disclosed |
| CN-114957053-A | Oxoethylene compound or pharmaceutically acceptable salt thereof, preparation method and application thereof, pharmaceutical composition and application thereof | 中国医学科学院医药生物技术研究所 | 2022-08-30 | — | — | CN | disclosed |
| CN-110885319-B | Sulfonamide compounds as sodium channel blockers and uses thereof | 成都康弘药业集团股份有限公司 | 2022-08-12 | — | — | CN | disclosed |
| US-7319099-B2 | Such as 1-{3-fluoro-4-[4-(2-isopropoxy-5-methanesulfonyl benzoyl)-piperazin-1-yl]-phenyl}-ethanone for treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia, attention deficit disorders, or Alzheimer's disease | HOFFMANN-LA ROCHE INC. (US) | 2008-01-15 | — | — | US | disclosed |
| EP-1656361-B1 | PIPERAZINE WITH OR-SUBSTITUTED PHENYL GROUP AND THEIR USE AS GLYT1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-01-02 | — | — | EP | disclosed |
| CN-101018773-A | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | ASTRAZENECA AB (SE) | 2007-08-15 | — | — | CN | disclosed |
| EP-1812426-A1 | ARYL SULFONAMIDE PERI-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE | Decode Genetics, Inc. (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006125972-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | WO | disclosed |
| US-20060142348-A1 | Aryl sulfonamide peri-substituted bicyclics for occlusive artery disease | DECODE CHEMISTRY, INC. (US) | 2006-06-29 | — | — | US | disclosed |
| EP-1656361-A1 | PIPERAZINE WITH OR-SUBSTITUTED PHENYL GROUP AND THEIR USE AS GLYT1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-17 | — | — | EP | disclosed |
| WO-2006044405-A1 | ARYL SULFONAMIDE PERI-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE | DECODE GENETICS, INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| US-20050209241-A1 | Benzoyl-piperazine derivatives | HOFFMANN-LA ROCHE INC. | 2005-09-22 | — | — | US | disclosed |
| WO-2005014563-A1 | PIPERAZINE WITH OR-SUBSTITUTED PHENYL GROUP AND THEIR USE AS GLYT1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209241-A1 | Benzoyl-piperazine derivatives | SLC1A2, SLC18A2, SLC6A7 | SLC1A3 12/4885SLC1A2 1/4885SLC1A1 4/4885 |
| US-11691949-B2 | Quinoline sulfonamide compounds and their use as antibacterial agents | NQO2, SDHA, SIRT5 | SLC1A3 3224/4885SLC1A2 2715/4885SLC1A1 2487/4885 |
| US-20060142348-A1 | Aryl sulfonamide peri-substituted bicyclics for occlusive artery disease | PTGIS, PTGIR, TBXA2R | SLC1A3 1939/4885SLC1A2 2028/4885SLC1A1 2010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.